Gastroenterology

Opinion: Embrace the Era of Next-Generation Biologics

November 21, 2020

Bincy P. Abraham, MD

Article

Bincy P. Abraham, MD, explains that even when payers allow coverage for biosimilars, providers may still be hesitant to use them.

Alvotech Files for US and EU Approval of Adalimumab Biosimilar

November 20, 2020

Tony Hagen

Article

The rheumatology and gastroenterology biosimilar candidate would enter the lucrative market established by Humira.

IGBA Launches Global Biosimilars Week

November 16, 2020

Tony Hagen

Article

The International Generic and Biosimilar Medicines Association (IGBA) hopes to build momentum for the use of biosimilars.

High Adherence Noted Among Infliximab Biosimilar Users

November 16, 2020

Tony Hagen

Article

Investigators looked at adherence in patients who switched from reference infliximab during treatment for rheumatologic and gastrointestinal treatment.

ACR Abstract Roundup: Pfizer and Celltrion Agents Demonstrate Safety, Efficacy

November 7, 2020

Tony Hagen

Article

Poster presentations at the American College of Rheumatology (ACR) Convergence 2020 meeting shed light on performance of adalimumab versions.

Celltrion's CT-P17 Adalimumab Biosimilar Candidate Demonstrates Equivalence

November 6, 2020

Tony Hagen

Article

Separate studies including one on application methods for CT-P17 were reported at the American College of Rheumatology Convergence 2020 meeting.

Study: Specialty Drug Spending Net of Rebates Soars for Private Insurance, Medicare Part D

November 2, 2020

Deana Ferreri, PhD

Article

This study of specialty drug spending looks beyond rebates to evaluate growth in spending from 2010 to 2017.

Ten Reasons Why Biosimilar Candidates Should Not Be Tested for Clinical Efficacy

October 31, 2020

Sarfaraz K. Niazi, PhD

Article

The FDA may require comparative clinical efficacy for biosimilar approval, but on top of all the other required and available evidence, these trials add little value, Sarfaraz K. Niazi, PhD, states.

Mvasi, Kanjinti Add Heft to Amgen's Third-Quarter Sales

October 29, 2020

Tony Hagen

Article

Amgen said its sales results for Mvasi (bevacizumab) and Kanjinti (trastuzumab) give it confidence that the US market for biosimilars is more viable than generally perceived.

Europeans Devise Checklist for Promoting Biosimilar Use

October 24, 2020

Deana Ferreri, PhD

Article

European investigators have derived a set of core principals for developing higher utilization of biosimilars.

x